Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-743,872 in Fluconazole-Unresponsive Oropharyngeal Candidiasis
NCT00005920Phase 2Terminated
- Sponsor
- Merck & Co.
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of caspofungin in oropharyngeal candidiasis (OPC) (2 arms), sponsored by Merck & Co. Primary endpoints: Safety and Tolerability and Efficacy up to 14 days. Status: terminated.
02
Drugs
caspofungin
03
Conditions
oropharyngeal candidiasis (OPC)
Beyond the preview
Go deeper on NCT00005920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005920.